Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant

This article was originally published in The Gray Sheet

Executive Summary

Rx Herculink Plus biliary stent system gains FDA market go-ahead for treatment of malignant biliary obstructions. Based on the previous generation Rx Herculink, the next-generation system incorporates an enhanced stent design to increase lesion coverage, Xcelon expansion balloon material for improved deliverability, and single-operator 0.014" guidewire. Separately, Guidant says it plans to pursue approval of an implantable defibrillator indication for those at risk of hereditary sudden unexplained death syndrome (SUDS), following a randomized, 61-patient Thai study. Data show that ICDs appear better than drugs in saving the lives of potential SUDS patients who have no structural heart disease and a normal ejection fraction. Of the 11 SUDS events, four beta-blocker patients died and seven ICD patients survived

Related Content

UsernamePublicRestriction

Register

MT014773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel